Extracellular vesicles from airway secretions: New insights in lung diseases

International Journal of Molecular Sciences Review Extracellular Vesicles from Airway Secretions: New Insights in Lung Diseases Laura Pastor 1, Elisabeth Vera 1,2, Jose M. Marin 1,2,3 and David Sanz-Rubio 1,*   Citation: Pastor, L.; Vera, E.; Marin, J.M.; Sanz-Rubio, D. Extracellular Vesicles from Airway Secretions: New Insights in Lung Diseases. Int. J. Mol. Sci. 2021,22, 583. https://doi.org/10.3390/ ijms22020583 Received: 9 December 2020 Accepted: 29 December 2020 Published: 8 January 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). 1Translational Research Unit, Instituto de Investigación Sanitaria de Aragón (IISAragón), Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain; [email protected] (L.P.); [email protected] (E.V.); [email protected] (J.M.M.) 2Respiratory Service, Hospital Universitario Miguel Servet, University of Zaragoza, 50009 Zaragoza, Spain 3Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERes), 28029 Madrid, Spain *Correspondence: davidsanzr[email protected] Abstract: Lung diseases (LD) are one of the most common causes of death worldwide. Although it is known that chronic airway inflammation and excessive tissue repair are processes associated with LD such as asthma, chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF), their specific pathways remain unclear. Extracellular vesicles (EVs) are heterogeneous nanoscale membrane vesicles with an important role in cell-to-cell communication. EVs are present in general biofluids as plasma or urine but also in secretions of the airway as bronchoalveolar lavage fluid (BALF), induced sputum (IS), nasal lavage (NL) or pharyngeal lavage. Alterations of airway EV cargo could be crucial for understanding LD. Airway EVs have shown a role in the pathogenesis of some LD such as eosinophil increase in asthma, the promotion of lung cancer in vitro models in COPD and as biomarkers to distinguishing IPF in patients with diffuse lung diseases. In addition, they also have a promising future as therapeutics for LD. In this review, we focus on the importance of airway secretions in LD, the pivotal role of EVs from those secretions on their pathophysiology and their potential for biomarker discovery. Keywords: extracellular vesicle; COPD; asthma; fibrosis; induced sputum; nasal lavage; oral lavage; bronchoalveolar lavage; exosome 1. Introduction Lung diseases (LD) are among the most common causes of death and disability worldwide [ 1 ]. According to the last updates of the Forum of International Respiratory Societies (FIRS), the high incidence of those pathologies is mainly due to global exposure to polluted air, particles, chemicals and infectious microorganisms [ 1 ]. Repeated exposures to these agents induce cell damage and trigger immune responses in the airway. Airway epithelium, which is the first line of defense against environmental agents, is damaged by this contact. Interactions and homeostasis between airway epithelium and mesenchymal, endothelial and immune cells in the airway and lungs are also modified [ 2 , 3 ]. Chronic airway inflammation and excessive tissue repair processes result in the development of LD such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) or lung cancer, as well as in systemic inflammation and associated co-morbidities [3–5]. Extracellular vesicles (EVs) are heterogeneous nanoscale membrane vesicles, including exosomes, microvesicles and apoptotic bodies, that are secreted by most cell types and they have been mainly described in plasma and serum [ 6 – 9 ] or urine. However, the presence of EVs has been also reported in secretions from airway such as saliva [ 10 ], induced sputum (IS) [ 11 ] or bronchoalveolar lavage fluid (BALF) [ 12 ]. EVs have emerged as a novel and crucial mechanism of intercellular communication [ 13 , 14 ] with an important role in inflammatory pathologies, including LD. Airway injury modifies EV cargo in lung epithelium derived-EVs promoting an immune response via macrophage activation [ 15 , 16 ]. Int. J. Mol. Sci. 2021,22, 583. https://doi.org/10.3390/ijms22020583 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021,22, 583 2 of 20 Therefore, EVs could contribute to clarify the molecular mechanisms underlying LD, but also they could provide new biomarkers among their cargo, as well as new EV-based therapeutic approaches [17,18]. In this review, we aim to summarize current knowledge about EVs related to LD. We will focus on the main LD such as COPD, asthma and IPF, and on the potential of airway secretions as source of new biomarkers. Finally, we suggest the potential function of EVs from these secretions in the pathophysiology of LD and their promising future as origin of biomarkers and for LD. 2. Lung Diseases 2.1. Asthma Asthma is one of the most prevalent chronic disease in developed countries in adults and children globally [1], affecting more than 339 million people [19] and 14% of children over the world [ 1 ]. Asthma is defined by the international Global Initiative for Asthma (GINA) as a heterogeneous disease related to chronic airway inflammation and characterized by intermittent episodes of wheeze, cough, dyspnea and chest tightness, as well as reversible airway limitation [ 19 ]. This disease shows different phenotypes and endotypes, depending on its mechanisms and responses to therapy [20]. Inflammation in asthma is extended from upper to peripheral airway revealing different molecular patterns. Most of the patients suffer allergic asthma characterized by Th2 immune response against environmental stimuli [ 21 ]. After antigen presentation, which is driven by dendritic cells [ 22 ], T-CD4 + lymphocytes secrete Th2-cytokines (IL-4, IL-13 and IL-5). IL-4 and IL-13 stimulate IgE production in B-cells [ 23 ], while IL-5 promotes eosinophil maturation in bone marrow and further eosinophil recruitment in the airway [ 21 , 24 ]. Non-allergic T2-eosinophilic response is pushed by alarmins and innate lymphoid cells 2, which are producers of Th2-cytokines, so they trigger eosinophilic inflammation in airway [ 25 ]. Finally, non-eosinophilic phenotype is normally related to more severe status and it is generally characterized by neutrophilic airway inflammation [ 25 , 26 ]. Although it is known that non-eosinophilic asthma pathophysiology is driven by Th17/Th1 cells [ 25 ] and cytokines as IL-17 and IL-22 [ 26 ], its molecular mechanisms are poorly understood. Airway epithelial injury produced by this inflammatory situation triggers asthma-characteristic airway remodeling, including the increase of airway smooth muscle bulk and mucus hypersecretion. Altogether, as shown in Figure 1, these phenomena produce airway narrowing and airway hyperresponsiveness to some environmental agents, which is also a characteristic feature of asthma [27,28]. 2.2. Chronic Obstructive Pulmonary Disease COPD has a noteworthy impact on global health, affecting more than 200 million people worldwide [ 1 ], leading mortality (3rd cause of death) and morbidity in the world [ 1 , 29 ]. COPD is a LD characterized by persistent airflow limitation and respiratory symptoms due to airway and/or alveolar damage. It is usually caused by significant exposure to irritants, especially cigarette smoke, although sometimes is influenced by host factors as abnormal lung development or α1 -antitripsin genetic deficiency [ 30 ]. COPD is associated to systemic inflammation, which is a risk factor to develop co-morbidities such as atherosclerosis and other cardiovascular diseases, diabetes, metabolic diseases or cancer [31,32]. Int. J. Mol. Sci. 2021,22, 583 3 of 20 Figure 1. Overview of the main processes and events that occur in different regions of lung and airway in asthma, chronic obstructive pulmonary disease (COPD) and interstitial pulmonary fibrosis (IPF) patients, compared to healthy condition. Asthma involves mainly the upper airway promoting airway remodeling, which includes airway smooth muscle hypertrophy and hyperplasia, and goblet cell hyperplasia and consequent mucus hypersecretion. These processes cause reversible airway narrowing. COPD affects lower airways and lung parenchyma causing irreversible airway narrowing and alveolar disruption (emphysema) in the lungs. IPF affects only the lungs through excessive fibrosis processes with subsequent aberrant alveolar re-epithelisation (broncholisation). (Components of this figure have been obtained and modified from Servier Medical Art, https://smart.servier.com, with permission under the Creative Commons Attribution 3.0 Unported License.). In contrast to asthma, inflammation in COPD is limited to peripheral airways and lung parenchyma, resulting in fibrosis, tissue destruction, small airway obstruction and emphysema [ 33 ]. These mechanisms are irreversible and produce progressive decline in lung function [ 5 ]. Different cells are involved in COPD inflammation processes: adaptative immune cells, innate immune cells (mainly neutrophils and macrophages) and structural cells. In response to cigarette smoke or other noxious particles, airway epithelial cells and macrophages are activated to produce several inflammatory mediators [ 34 ]. The transcription factor NFκβ , activated in alveolar COPD macrophages [ 35 ], up-regulates the expression of inflammatory molecules [ 36 ]. Neutrophils from peripheral airway release CXCL8, promoting autocrine neutrophil recruitment and several proteinases, which contribute to loss of elasticity and peripheral airway collapse. This processes, together with profibrotic effect of TGFβ released from epithelial cells and macrophages, result in alveolar destruction, fibrosis and irreversible airway narrowing [ 36 ] (Figure 1). Lungs of COPD patients also suffer an accelerated ageing produced by an abnormal accumulation of senescent structural cells [ 37 ]. Finally, eosinophils have been reported to be increased in Int. J. Mol. Sci. 2021,22, 583 4 of 20 airway of some COPD patients, suggesting the existence of a different COPD phenotype whose molecular mechanisms are poorly understood [38]. 2.3. Idiopathic Pulmonary Fibrosis IPF is increasing over the time worldwide with an estimated incidence of 2.8–18 cases/100,000 people per year in Europe and North America. Lower incidence is defined in Asia and South America, which may be partially due to under-diagnosis [ 39 ]. In addition, IPF is more frequent in men [ 40 ]. IPF is a chronic, progressive fibrosing interstitial pneumonia of unknown etiology that usually affects to older adults. Disease progression varies between patients and is unpredictable, but IPF leads to severe pathological processes which end in premature death [41]. Molecular mechanisms of IPF are not fully understood although chronic dysregulation in alveolar epithelial cells homeostasis has been described (Figure 1). IPF biopsies show loss of type 1 alveolar epithelial cells (AEC1s) and reduced abnormal renewal capacity in type 2 (AEC2s) [ 42 , 43 ]. Fibroblast aggrupation are also observed between abnormal AECs [ 44 , 45 ]. In response to these microinjuries, remaining AECs are activated to release fibrogenic growth factors and cytokines, resulting in the recruitment of myofibroblast from different sources [ 45 – 47 ]. At this location, myofibroblasts increase secretion of abnormal extracellular matrix components, whose accumulation and deposition leads to fibrosis and gas exchange impairment. It also enhances myofibroblast activation, establishing a positive feedback process [ 48 ]. In addition, peripheral airway basal cells act as stem cells to repair damaged alveolar airway with new epithelial cells, known as broncholisation [49–51]. 3. Airway Secretions Sampling the upper and lower airways is a remarkably helpful tool in clinical practice. Different airway secretions are used and has been lately investigated as a promising source of biomarkers, including bronchoalveolar lavage fluid (BALF), induced sputum (IS), nasal lavage fluid (NL) or pharyngeal lavage fluid (PHAL). 3.1. Bronchoalveolar Lavage Fluid BALF is an established procedure for washing the bronchial tree with saline which allows sampling peripheral airways [ 52 ]. It is an invasive method, as it is performed together with a flexible fiberoptic bronchoscopy. BALF contains the cells in the alveolar space which have been in contact with the instilled fluid (alveolar macrophages, CD4 + and CD8 + lymphocytes, neutrophils, eosinophils and mast cells [ 53 ]), airway epithelial cells (contaminating BALF if exceed 5% of total cell count [ 53 ]), and different soluble components from the endogenous fluid in the alveoli, named the epithelial lining fluid (ELF) [ 54 ]. These components proceed mainly from local cell secretory production [ 55 – 57 ], but also from the vascular space in contact with the alveolar space [ 54 ]. In clinical practice, BALF is used in diagnosis of respiratory infections [ 58 ] and as a part of the diagnosis or in characterization of non-infective LD, both in adults and children [ 59 ]. However, its invasive nature has limited its use as a research tool. 3.2. Induced Sputum Sputum induction is a relatively non-invasive method to collect a sample of cells and secretions from lower airways as shown in Figure 2[ 60 ]. Sputum is induced by inhalation of hypertonic or isotonic sterile saline solution and obtained by further direct expectoration [ 61 ]. IS is a safer and less invasive method to sample ELF than BALF [ 62 , 63 ]. However, IS contains also saliva and squamous cells from upper airways, which are considered contaminant components and represent different proportions of IS [64,65]. Int. J. Mol. Sci. 2021,22, 583 5 of 20 Figure 2. Anatomical origin of minimally invasive and non-invasive airway secretions. Induced sputum comes from lower airway while nasal lavage and pharyngeal lavage have their origin in different parts of the upper airway. (Components of this figure have been obtained and modified from Servier Medical Art, https://smart.servier.com, with permission under the Creative Commons Attribution 3.0 Unported License.). Most of IS research has been dedicated to asthma, although multitude of studies have investigated the utility of IS in other LD, especially COPD and chronic cough [ 66 ]. Differential cell count in IS is used in clinical practice to assess asthma phenotypes [ 67 ], although reference parameters vary among different studies and populations [ 68 – 70 ]. In both asthma [ 71 ] and COPD [ 72 ], cultures from IS are performed to identify the presence of pathogens and manage antibiotic therapy. Extended biomarkers research has been done in IS. For example, assessment of inflammatory pattern of exacerbations in asthma and COPD by IS cytology allows therapy adjustment and prediction of new exacerbation episodes [ 73 ]. IS can work as a minimally invasive BALF surrogate in assessment of low airway status in LD with low airway involvement, although further research is needed in order to optimize protocols and standardize reference parameters. In this way, IS has been proposed and studied as a non-invasive surrogate of BALF in interstitial LD diagnosis [74]. 3.3. Nasal Lavage Fluid NL is a non-invasive procedure to obtain cytology from nasal cavities [ 75 ] (Figure 2). Different nasal lavage techniques have been described [ 76 , 77 ] consisting on instill sterile saline solution. NL is a mixture of saline and nasal secretions, containing epithelial cells, neutrophils, eosinophils, lymphocytes and their secreted mediators [78]. NL has been applied to assess the inflammatory status of a specific part of upper airways, the nasal cavities. Most NL studies have been focused in rhinitis, as it is a disease characterized by nasal mucosa inflammation and nasal hypersecretion [ 75 , 78 , 79 ]. Recent studies have shown that NL cytology is a best substitute for IS cytology than blood cell count in identification of inflammatory phenotypes of asthma [ 80 , 81 ]. In addition, despite the weaker relationship between nasal mucosa inflammation and COPD, another work revealed that IL-8 concentration in NL have positive correlation with disease severity and cigarette pack-years in COPD patients [ 82 ]. NL has a great potential as a non-invasive substitute of IS in those patients or situations where perform IS could be risked. 3.4. Pharyngeal Lavage Fluid PHAL is a recently developed non-invasive technique to collect cells from the oropharyngeal cavity to assess mucosal inflammation of the upper airway [ 83 ]. Figure 2shows that PHAL contains cells from the oropharyngeal mucosa (a major proportion of squamous Int. J. Mol. Sci. 2021,22, 583 6 of 20 epithelial cells, followed by a high percentage of neutrophils and other inflammatory cells [83]) and soluble factors and proteins [84]. Higher PHAL lymphocytes number have been found in the patients with obstructive sleep apnea (OSA) [ 85 , 86 ]. Our group reported also that T-CD4 + cells number in PHAL correlated with more severe OSA status, as well as PHAL concentration of IL-6 and IL-8 [ 84 ]. Thus, PHAL is emerging as a new non-invasive tool to assess upper airway inflammation, which could be particularly helpful in some LD with concomitant upper airway inflammation such as asthma. 4. Extracellular Vesicles EVs are a heterogeneous population of small membranous structures released into the extracellular environment by most cells and participate in intercellular communication [ 87 ]. EVs have been classified according to different criteria as their size or biogenesis, differentiating between exosomes, microvesicles (MVs), and apoptotic bodies (ABs) [ 88 – 90 ]. Exosomes (30–150 nm) result from a complex biogenesis which involves the endosomal membrane invagination, generating intraluminal vesicles (ILVs) inside the late endosome (MVB), and the fusion between the MVB membrane and the plasma membrane releases exosomes [ 91 , 92 ]. MVs (100 nm to 1000 nm), also named ectosomes or microparticles, are generated directly by outward budding of the plasma membrane [ 93 , 94 ]. ABs (1 to 5 µ m) are released undergoing apoptosis, via plasma membrane bubbling or fragmentation due to cell disassembly [95,96]. EVs contain biomolecules from their origin cell, including proteins, lipids, metabolites and different nucleic acids (DNA, mRNA, miRNA and other noncoding RNA) [89,97,98]. Their molecular cargo can be uploaded into the vesicles selectively, mostly in exosomes. This process depends on cell status and type [ 99 ]. EV release has been reported in platelets [ 93 ], tumor cells [ 100 ], dendritic cells [ 101 ], T [ 102 ] and B [ 103 ] cells, eosinophils [ 104 ], epithelial cells [ 15 , 16 ], endothelial cells [ 105 ] or mesenchymal stem cells (MSCs) [ 106 ]. Their accessibility in body fluids (plasma [ 6 , 8 ], serum [ 9 ], urine [ 9 ], saliva [ 10 ], BALF [ 12 ] or IS [ 11 ]) and the specificity of their cargo associated with pathophysiological conditions [ 107 , 108 ] confer them great potential as biomarkers. EVs have been broadly studied because of their association with pathologies, including inflammatory diseases [ 109 , 110 ] cardiovascular diseases [ 111 , 112 ], metabolic diseases [113,114] , cancer [ 115 , 116 ] or LD [ 107 , 117 , 118 ]. They have been linked to pro-inflammatory processes, participating in antigen presentation [ 101 , 103 ] or macrophage activation [ 15 ], as well as to immunomodulatory processes [ 106 ]. Additionally, EVs could have a therapeutic approach as vehicles for drug delivery, given their intrinsic biocompatibility and specific target activity [ 119 ]. Promising examples of it are novel exosome-based modality of cancer therapy [120] or nanoparticle-guided asthma therapy [121]. In the last decade, the research on EVs has increased. However, the optimal isolation method remains unclear and most times depends on the downstream analyses [ 13 , 122 – 124 ]. Their characterization requires follow several points that include protein markers, size or morphology. Those are described in the MISEV2018 [ 87 ] updating the MISEV2014 [ 125 ], showing that the EV field is continuously in development and requires further stu-dies. 5. EVs in Lung Pathophysiology Most lung cells release EVs under physiological and pathological conditions. Bronchial epithelial cells (BECs) and alveolar macrophages are the major sources of pulmonary EVs [ 126 ], but also vascular endothelial cells, fibroblasts, MSCs and dendritic cells. All together are involved in lung homeostasis, as well as in LD development. Transfer of EVs cargo between airway epithelial cells can alter the secretions of their target cells, including mucins [ 127 ]. Membrane associated mucins are present in tracheobronchial epithelial cells exosomes surface, suggesting their contribution to innate mucosal defense of airway [ 128 ]. Similarly, alveolar macrophages release EVs that contain the suppressor of cytokines signaling (SOCS) 1 and 3. These EVs have immunomodulatory effects Int. J. Mol. Sci. 2021,22, 583 7 of 20 in the alveolar epithelial cells and their secretion is diminished by cigarette smoking [ 129 ]. Table 1shows some of the proteins, lipids and miRNAs contained in EVs that have been related with asthma, COPD and IPF. Table 1. Proteins, lipids and miRNAs contained in extracellular vesicles (EVs) that have been associated with asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). EV Cargo Asthma COPD IPF Proteins ADAM10 [11], MHC-II [101,103,130], HLA-DR (IS) [11] α1-antitrypsin [131], CD66b [132,133], CD31, NE [132]Tissue factor [134], WNT5A [135] Lipids Leukotriene B4 [136] PGE2 [137] miRNAs miR-223 and miR-142a [ 138 ], let-7, miR-200 families, miR-21 [139] miR-210 [140], miR-21 [141], Let-7e, let-7g, miR-26b [142] miR-21 [143], miR-328 [144], miR-33a, miR-142 and let-7d [ 145 ] 5.1. EVs in Asthma EVs are involved in several processes of asthma immunity and inflammation. One of the most important is antigen presentation ability of EVs released from dendritic cells [ 101 ] and B cells [ 103 , 130 ]. Figure 3shows that MHC-II and co-stimulatory molecules in the surfaces of these EVs allow interaction with T cells and subsequent differentiation of T cells, proliferation of T-CD4+Th2 cells and secretion of Th2 cytokines [101,130]. Asthma-like inflammation driven by IL-13 enhances exosomes secretion in BECs inducing proliferation and chemotaxis of undifferentiated macrophages in the lungs [ 126 ]. Bronchoconstriction mechanical stress also stimulates exosomes secretion from BECs, producing typical subepithelial angiogenesis [ 146 ]. Furthermore, mechanical signals regulate miRNA cargo of EVs released from BECs [ 147 ]. In contrast, EV immunomodulatory effects has been reported to be diminished in asthma, such as EV-mediated transport of SOCS3 from alveolar macrophages to BECs [148]. Eosinophil exosomes of asthmatic patients differ their capacities from non-asthmatic subjects. They promote eosinophil chemotaxis increasing ROS and nitric oxide (NO) levels, and adhesion, via ICAM-1 and integrinα2 upregulation [ 149 ] (Figure 3). These exosomes also promote apoptosis and reduce wound healing capacity in BECs via TNF or CCL26 upregulation [ 150 ]. In addition, their angiogenic effect on bronchial smooth muscle cells is mediated by VEGFA [ 150 ]. Similarly, exosomes from neutrophils enhance neutrophils chemotaxis through their leukotriene B4 cargo [ 136 ] and adhesion by ICAM-1 upregulation in lung endothelial cells [151]. Few studies describe the effect of asthma pathophysiology on EV-miRNAs [ 152 ]. One of them described the increase of miR-223 and miR-142a on EVs from BALF of allergentreated mice [ 138 ] while other, performed on asthmatic patients, described 24 miRNAs differentially expressed including members of let-7 and miR-200 families and miR-21 [ 139 ]. MiR-21 targets the pro-inflammatory Th1 cytokine, IL-12, and downregulate Th2 response, which is characteristic of asthma inflammation [ 153 ]. Accordingly, miR-21 is increased in serum of asthmatic patients and inversely correlated with FEV 1 [ 154 ]. Lastly, a set of EV-miRNAs from BALF and miRNAs from lung tissue were altered in allergen-exposed mice and were inversely correlated between both origins [155]. Int. J. Mol. Sci. 2021,22, 583 8 of 20 Figure 3. Summary of some of the main reported roles of extracellular vesicles (EVs) in the pathophysiological mechanisms of asthma, chronic obstructive pulmonary disease (COPD) and interstitial pulmonary fibrosis (IPF). The figure shows the cellular origin of the EVs as well as their cellular destiny or their main action. In the upper and large lower airway of asthma patients, EVs contribute to antigen presentation, EVs from endothelial cells participate in macrophage chemotaxis while eosinophil EVs could act in their own chemotaxis, adhesion and recruitment. In COPD, EVs could promote emphysema development increasing MMP1 secretion in lung epithelial cells, through myofibroblast differentiation or enhancing the proteolysis of the extracellular matrix. In the alveoli of IPF patients, EVs from macrophages could increase the collagen 1-A expression in fibroblast, increasing the extracellular matrix deposition, as well as promote fibroblast proliferation. (Components of this figure have been obtained and modified from Servier Medical Art, https://smart.servier.com, with permission under the Creative Commons Attribution 3.0 Unported License.). 5.2. EVs in COPD EVs may also play a main role in COPD pathophysiology. One of the factors associated with COPD, cigarette smoke (CS), modifies EV cargo from different lung cells. CS induces significant release of CCN1-enriched exosomes from BECs, as well as the cleavage of matrixassociated CCN family protein into a shorter isoform [156], which promotes MMP1 secretion in lung epithelial cells contributing to emphysema development [156–158] (Figure 3) . Similarly, macrophages exposed to CS release MVs with proteolytic and collagenolytic activity in their surface as shown in Figure 3[ 159 ]. In addition, the increased macrophageMVs release upregulates several pro-inflammatory and chemoattractant mediators, as ICAM-1, IL-8 and MCP-1, in alveolar epithelial cells [ 160 ]. Other studies have focused on EV non-coding RNAs in smokers and COPD patients. MiR-210 is overexpressed in both BEC-EVs and lung tissue samples after CS exposure. miR-210 loaded-EVs from COPD patients showed the induction of lung fibroblasts differentiation into myofibroblasts by silencing the autophagy-related factor ATG7 [ 140 ]. Different profiles of long non-coding RNAs (lncRNAs) were found in circulating exosomes from non-smokers and smokers of different smoking products. EV-lncRNAs alterations found in smokers could lead to pulmonary fibrosis and mitophagy, which are hallmark processes in COPD and IPF. In addition, the targets of some of the differential lncRNAs are involved in pathological processes of COPD, IPF and asthma [161]. Int. J. Mol. Sci. 2021,22, 583 9 of 20 Overexpression of exosomal miR-21 from BECs also promotes myofibroblast differentiation targeting hypoxia-inducible factor 1 α (HIF-1 α ) [ 141 ]. However, decreased miR-21 was observed in BEC exosomes exposed to CS. This compensatory mechanism in response to CS reduced M2 macrophage polarization and, consequently, epithelial-mesenchymal transition involved in airway remodeling [ 162 ]. Finally, CS induce on endothelial cells the production of MVs enriched in let-7d, miR-191, miR-126 and miR-125a, whose major effect in recipient macrophages was the impairment of efferocytosis [163]. Surface proteins identified in circulating endothelial MVs suggest that endothelial MVs have an important regulatory role in the coagulation and inflammation processes in COPD [ 164 ]. It has been also reported that EV-mediated transport of α1 -antitrypsin from endothelial cells to alveolar epithelial cells is impaired by CS exposure [ 131 ]. In addition, exosomes from activated neutrophils contain neutrophil elastase (NE) in their surfaces, protecting NE from α1 -antitrypsin proteolysis, and enabling the degradation of the extracellular matrix via NE + exosomes [ 132 ] (Figure 3). These results suggest that endothelial and neutrophil derived-EVs contribute to emphysema development in COPD. 5.3. EVs in IPF EVs implication in IPF remains unclear. Up to now, mostly EV studies related to mechanisms involved in fibrosis development used in vitro or murine models and focused their miRNA cargo. MiR-21 is upregulated in EVs from serum of a lung fibrosis mice model and from human IPF patients and it is correlated with IPF progression and mortality [ 143 ]. Another study showed that miR-21 upregulation is promoted via TGFβ 1 and it has profibrotic effects including myofibroblast differentiation as described in Figure 3[ 165 ]. Kidney epithelial cells have been reported to release an increased amount of exosomes in response to injury, loaded with specific pro-fibrotic cargo such as TGFβ 1 mRNA, which produce fibroblasts proliferation, activation and repair processes [166]. On an IPF rat model, miR-328 was overexpressed in M2 macrophage-derived exosomes with associated proliferative effects in fibroblasts via silencing FAM13A and overexpression of certain proteins as collagen 1A and α -SMA (Figure 3) [ 144 ]. Three more exosomal microRNAs have been reported to be altered in IS from IPF patients, miR-33a, miR-142 and let-7d [145]. Lastly, a recent study showed increase amount of EVs carrying WNT5A in BALF from IPF patients. These EVs originating from lung fibroblasts have autocrine effects in vitro stimulating fibroblast proliferation [ 135 ]. Impairment or block of EV-WNT5A suppresses the fibrogenic effects of EVs improving the IPF pathology. 6. EVs in Airway Secretions and Potential Utility in Clinical Practice Presence of EVs in airway secretions was first described on BALF of healthy subjects [ 12 ]. By contrast, the isolation of EVs from sputum was reported 13 years later from spontaneous sputum of cystic fibrosis patients [ 167 ]. Following we present the emerging relevance of EVs from airways secretion on LD. 6.1. Airway EVs in Asthma The vast majority of EV studies in patients with asthma have been done using BALF. Increased amount of exosomes with specific protein surface markers [ 168 ], lipid [ 168 ] and miRNA [ 139 ] profiles were found in BALF of asthmatic patients. Exosome concentration and expression of altered EV-miRNAs were correlated with asthma severity biomarkers such as serum eosinophil and IgE levels [ 168 ] and FEV 1 [ 139 ]. Up to now, only one work has recovered EVs from IS of asthmatic patients [ 11 ]. Exosomes from IS of mild allergic asthma patients contain short RNA species and surface markers as tetraspanins and HLA-DR, suggesting the feasibility of IS as an accessible minimally-invasive source of EV biomarkers [11]. EVs were isolated from NL for the first time on 2011 [ 169 ]. More than 600 proteins have been identified among NL-EV cargo, finding proteins related with antimicrobial Int. J. Mol. Sci. 2021,22, 583 16 of 20 83. Hauber, H.P.; Rüller, S.; Müller Peter, E.; Peter, Z. Comparison of Differential Cell Counts in Pharyngeal Lavage from Patients with Obstructive Sleep Apnea and from Healthy Control Persons. Atemwegsund Lungenkrankheiten 2009 ,35, 373–378. [CrossRef] 84. Vicente, E.; Marin, J.M.; Carrizo, S.J.; Osuna, C.S.; González, R.; Marin-Oto, M.; Forner, M.; Vicente, P.; Cubero, P.; Gil, A.V.; et al. Upper airway and systemic inflammation in obstructive sleep apnoea. Eur. Respir. J. 2016,48, 1108–1117. [CrossRef] 85. I Baess, A.; E Mohamed, E.; Eldowik, Y.M. Study of upper airway inflammation in patients with obstructive sleep apnea–hypopnea syndrome. Egypt. J. Bronchol. 2019,13, 754. [CrossRef] 86. Hauber, H.-P.; Rüller, S.; Müller, E.; Hansen, E.; Zabel, P. Pharyngeal Lavage Lymphocytosis in Patients with Obstructive Sleep Apnea: A Preliminary Observation. PLoS ONE 2011,6, e16277. [CrossRef] [PubMed] 87. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 2018 ,7, 1535750. [CrossRef] 88. György, B.; Szabó, T.G.; Pásztói, M.; Pál, Z.; Misják, P.; Aradi, B.; László, V.; Pállinger, É.; Pap, E.; Kittel, Á.; et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011 ,68, 2667–2688. [CrossRef] [PubMed] 89. Pathan, M.; Fonseka, P.; Chitti, S.V.; Kang, T.; Sanwlani, R.; Van Deun, J.; Hendrix, A.; Mathivanan, S. Vesiclepedia 2019: A compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2019 ,47, D516–D519. [CrossRef] [PubMed] 90. Mathieu, M.; Martin-Jaular, L.; Lavieu, G.; Théry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 2019,21, 9–17. [CrossRef] 91. Johnstone, R.M.; Adam, M.; Hammond, J.R.; Orr, L.; Turbide, C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 1987,262, 9412–9420. [CrossRef] 92. Kowal, J.; Tkach, M.; Théry, C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 2014,29, 116–125. [CrossRef] 93. Heijnen, H.F.; Schiel, A.E.; Fijnheer, R.; Geuze, H.J.; Sixma, J.J. Activated Platelets Release Two Types of Membrane Vesicles: Microvesicles by Surface Shedding and Exosomes Derived From Exocytosis of Multivesicular Bodies and -Granules. Blood 1999 , 94, 3791–3799. [CrossRef] 94. Cocucci, E.; Meldolesi, J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015 , 25, 364–372. [CrossRef] 95. Kerr, J.F.R.; Wyllie, A.H.; Currie, A.R. Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics. Br. J. Cancer 1972,26, 239–257. [CrossRef] [PubMed] 96. Atkin-Smith, G.K.; Tixeira, R.; Paone, S.; Mathivanan, S.; Collins, C.; Liem, M.; Goodall, K.J.; Ravichandran, K.S.; Hulett, M.D.; Poon, I.K.H. A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. Nat. Commun. 2015,6, 7439. [CrossRef] [PubMed] 97. Wubbolts, R.; Leckie, R.S.; Veenhuizen, P.T.M.; Schwarzmann, G.; Möbius, W.; Hoernschemeyer, J.; Slot, J.W.; Geuze, H.J.; Stoorvogel, W. Proteomic and Biochemical Analyses of Human B Cell-Derived Exosomes: Potential Implications for Their Function and Multivesicular Body Formation. J. Biol. Chem. 2003,278, 10963–10972. [CrossRef] [PubMed] 98. Crescitelli, R.; Lässer, C.; Szabó, T.G.; Kittel, A.; Eldh, M.; Dianzani, I.; Buzás, E.I.; Lotvall, J. Distinct RNA profiles in subpopulations of extracellular vesicles: Apoptotic bodies, microvesicles and exosomes. J. Extracell. Vesicles 2013 ,2. [CrossRef] [PubMed] 99. Anand, S.; Samuel, M.; Kumar, S.; Mathivanan, S. Ticket to a bubble ride: Cargo sorting into exosomes and extracellular vesicles. Biochim. Biophys. Acta (BBA)—Proteins Proteom. 2019,1867, 140203. [CrossRef] [PubMed] 100. Wolfers, J.; Lozier, A.; Raposo, G.; Regnault, A.; Théry, C.; Masurier, C.; Flament, C.; Pouzieux, S.; Faure, F.; Tursz, T.; et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001 ,7, 297–303. [CrossRef] 101. Vallhov, H.; Gutzeit, C.; Hultenby, K.; Valenta, R.; Gronlund, H.; Scheynius, A. Dendritic cell-derived exosomes carry the major cat allergen Fel d 1 and induce an allergic immune response. Allergy 2015,70, 1651–1655. [CrossRef] [PubMed] 102. Blanchard, N.; Lankar, D.; Faure, F.; Regnault, A.; Dumont, C.; Raposo, G.; Hivroz, C. TCR Activation of Human T Cells Induces the Production of Exosomes Bearing the TCR/CD3/ζComplex. J. Immunol. 2002,168, 3235–3241. [CrossRef] 103. Raposo, G.; Nijman, H.W.; Stoorvogel, W.; Liejendekker, R.; Harding, C.V.; Melief, C.J.; Geuze, H.J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996,183, 1161–1172. [CrossRef] 104. Mazzeo, C.; Cañas, J.A.; Zafra, M.P.; Mar, F.-N.; Fernández-Nieto, M.; Sanz, V.; Mittelbrunn, M.; Izquierdo, M.; Baixaulli, F.; Sastre, J.; et al . Exosome secretion by eosinophils: A possible role in asthma pathogenesis. J. Allergy Clin. Immunol. 2015 ,135, 1603–1613. [CrossRef] 105. Hristov, M.; Erl, W.; Linder, S.; Weber, P.C. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood 2004,104, 2761–2766. [CrossRef] 106. Qiu, G.; Zheng, G.; Ge, M.; Wang, J.; Huang, R.; Shu, Q.; Xu, J. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res. Ther. 2018,9, 1–9. [CrossRef] [PubMed] 107. Riancho, J.; Sánchez-Juan, P. Circulating Extracellular Vesicles in Human Disease. N. Engl. J. Med. 2018 ,379, 2179–2181. [CrossRef] Int. J. Mol. Sci. 2021,22, 583 17 of 20 108. De Toro, J.; Herschlik, L.; Waldner, C.; Mongini, C. Emerging Roles of Exosomes in Normal and Pathological Conditions: New Insights for Diagnosis and Therapeutic Applications. Front. Immunol. 2015,6, 203. [CrossRef] [PubMed] 109. Chimen, M.; Evryviadou, A.; Box, C.L.; Harrison, M.J.; Hazeldine, J.; Dib, L.H.; Kuravi, S.J.; Payne, H.; Price, J.M.; Kavanagh, D.; et al. Appropriation of GPIb α from platelet-derived extracellular vesicles supports monocyte recruitment in systemic inflammation. Haematologica 2019,105, 1248–1261. [CrossRef] 110. Zulueta, A.; Peli, V.; Cas, M.D.; Colombo, M.; Paroni, R.; Falleni, M.; Baisi, A.; Bollati, V.; Chiaramonte, R.; Del Favero, E.; et al. Inflammatory role of extracellular sphingolipids in Cystic Fibrosis. Int. J. Biochem. Cell Biol. 2019,116, 105622. [CrossRef] 111. Wadey, R.M.; Connolly, K.D.; Mathew, D.; Walters, G.; Rees, D.A.; E James, P. Inflammatory adipocyte-derived extracellular vesicles promote leukocyte attachment to vascular endothelial cells. Atherosclerosis 2019,283, 19–27. [CrossRef] 112. Goetzl, E.J.; Schwartz, J.B.; Mustapic, M.; Lobach, I.V.; Daneman, R.; Abner, E.L.; Jicha, G.A. Altered cargo proteins of human plasma endothelial cell–derived exosomes in atherosclerotic cerebrovascular disease. FASEB J. 2017,31, 3689–3694. [CrossRef] 113. Chang, W.; Wang, J. Exosomes and Their Noncoding RNA Cargo Are Emerging as New Modulators for Diabetes Mellitus. Cells 2019,8, 853. [CrossRef] 114. Li, F.; Li, H.; Jin, X.; Zhang, Y.; Kang, X.; Zhang, Z.; Xu, M.; Qian, Z.; Ma, Z.; Gao, X.; et al. Adipose-specific knockdown of Sirt1 results in obesity and insulin resistance by promoting exosomes release. Cell Cycle 2019,18, 2067–2082. [CrossRef] 115. Bell, E.; A Taylor, M. Functional Roles for Exosomal MicroRNAs in the Tumour Microenvironment. Comput. Struct. Biotechnol. J. 2017,15, 8–13. [CrossRef] 116. Steinbichler, T.B.; Dudás, J.; Riechelmann, H.; Skvortsova, I.-I. The role of exosomes in cancer metastasis. Semin. Cancer Biol. 2017 , 44, 170–181. [CrossRef] 117. Chen, J.; Hu, C.; Pan, P. Extracellular Vesicle MicroRNA Transfer in Lung Diseases. Front. Physiol. 2017,8. [CrossRef] 118. Kubo, H. Extracellular Vesicles in Lung Disease. Chest 2018,153, 210–216. [CrossRef] [PubMed] 119. Lässer, C.; Jang, S.C.; Lötvall, J. Subpopulations of extracellular vesicles and their therapeutic potential. Mol. Asp. Med. 2018 ,60, 1–14. [CrossRef] [PubMed] 120. Sancho-Albero, M.; Rubio-Ruiz, B.; Pérez-López, A.M.; Sebastian, V.; Martín-Duque, P.; Arruebo, M.; Santamaria, J.; Unciti-Broceta, A. Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis. Nat. Catal. 2019 ,2, 864–872. [CrossRef] [PubMed] 121. Kan, S.; Hariyadi, D.M.; Grainge, C.; Knight, D.; Bartlett, N.W.; Liang, M. Airway epithelial-targeted nanoparticles for asthma therapy. Am. J. Physiol. Cell. Mol. Physiol. 2020,318, L500–L509. [CrossRef] 122. Sanz-Rubio, D.; Martín-Burriel, I.; Gil, A.; Cubero, P.; Forner, M.; Khalyfa, A.; Marin, J.M. Stability of Circulating Exosomal miRNAs in Healthy Subjects. Sci. Rep. 2018,8, 10306. [CrossRef] 123. Taylor, D.D.; Shah, S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods 2015 ,87, 3–10. [CrossRef] 124. Patel, G.K.; Khan, M.A.; Zubair, H.; Srivastava, S.K.; Khushman, M.; Singh, S.; Singh, A.P. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep. 2019 ,9, 5335. [CrossRef] 125. Lötvall, J.; Hill, A.F.; Hochberg, F.; Buzás, E.I.; Di Vizio, D.; Gardiner, C.; Gho, Y.S.; Kurochkin, I.V.; Mathivanan, S.; Quesenberry, P.; et al . Minimal Experimental Requirements for Definition of Extracellular Vesicles and their Functions: A Position Statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 2014,3, 26913. [CrossRef] [PubMed] 126. Kulshreshtha, A.; Ahmad, T.; Agrawal, A.; Ghosh, B. Proinflammatory role of epithelial cell–derived exosomes in allergic airway inflammation. J. Allergy Clin. Immunol. 2013,131, 1194–1203.e14. [CrossRef] [PubMed] 127. Gupta, R.; Radicioni, G.; Abdelwahab, S.; Dang, H.; Carpenter, J.; Chua, M.; Mieczkowski, P.A.; Sheridan, J.T.; Randell, S.H.; Kesimer, M. Intercellular Communication between Airway Epithelial Cells Is Mediated by Exosome-Like Vesicles. Am. J. Respir. Cell Mol. Biol. 2019,60, 209–220. [CrossRef] [PubMed] 128. Kesimer, M.; Scull, M.; Brighton, B.; DeMaria, G.; Burns, K.; O’Neal, W.; Pickles, R.J.; Sheehan, J.K. Characterization of exosomelike vesicles released from human tracheobronchial ciliated epithelium: A possible role in innate defense. FASEB J. 2009 ,23, 1858–1868. [CrossRef] 129. Bourdonnay, E.; Zasłona, Z.; Penke, L.R.K.; Speth, J.M.; Schneider, D.J.; Przybranowski, S.; Swanson, J.A.; Mancuso, P.; Freeman, C.M.; Curtis, J.L.; et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J. Exp. Med. 2015,212, 729–742. [CrossRef] 130. Admyre, C.; Bohle, B.; Johansson, S.M.; Focke-Tejkl, M.; Valenta, R.; Scheynius, A.; Gabrielsson, S. B cell–derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. J. Allergy Clin. Immunol. 2007,120, 1418–1424. [CrossRef] 131. Lockett, A.D.; Brown, M.B.; Santos-Falcon, N.; Rush, N.I.; Oueini, H.; Oberle, A.J.; Bolanis, E.; Fragoso, M.A.; Petrusca, D.N.; Serban, K.A.; et al. Active Trafficking of Alpha 1 Antitrypsin across the Lung Endothelium. PLoS ONE 2014 ,9, e93979. [CrossRef] 132. Genschmer, K.R.; Russell, D.W.; Lal, C.; Szul, T.; Bratcher, P.E.; Noerager, B.D.; Roda, M.A.; Xu, X.; Rezonzew, G.; Viera, L.; et al. Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung. Cell 2019 ,176, 113–126.e15. [CrossRef] 133. Porro, C.; Lacedonia, D.; Carpagnano, G.E.; Trotta, T.; Palladino, G.P.; Panaro, M.A.; Zoppo, L.D.; Foschino, M.P. Microparticles in sputum of COPD patients: A potential biomarker of the disease? Int. J. Chronic Obstr. Pulm. Dis. 2016,11, 527–533. [CrossRef] Int. J. Mol. Sci. 2021,22, 583 18 of 20 134. Novelli, F.; Neri, T.; Tavanti, L.; Armani, C.; Noce, C.; Falaschi, F.; Bartoli, M.L.; Martino, F.; Palla, A.; Celi, A.; et al. Procoagulant, Tissue Factor-Bearing Microparticles in Bronchoalveolar Lavage of Interstitial Lung Disease Patients: An Observational Study. PLoS ONE 2014,9, e95013. [CrossRef] 135. Martin-Medina, A.; Lehmann, M.; Burgy, O.; Hermann, S.; Baarsma, H.A.; Wagner, D.E.; De Santis, M.M.; Ciolek, F.; Hofer, T.P.; Frankenberger, M.; et al. Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2018,198, 1527–1538. [CrossRef] [PubMed] 136. Majumdar, R.; Tameh, A.T.; Parent, C.A. Exosomes Mediate LTB4 Release during Neutrophil Chemotaxis. PLoS Biol. 2016 ,14, e1002336. [CrossRef] [PubMed] 137. Lacy, S.H.; Woeller, C.F.; Thatcher, T.H.; Pollock, S.J.; Small, E.M.; Sime, P.J.; Phipps, R.P. Activated Human Lung Fibroblasts Produce Extracellular Vesicles with Antifibrotic Prostaglandins. Am. J. Respir. Cell Mol. Biol. 2019 ,60, 269–278. [CrossRef] [PubMed] 138. Pua, H.H.; Happ, H.C.; Gray, C.J.; Mar, D.J.; Chiou, N.-T.; Hesse, L.E.; Ansel, K.M. Increased Hematopoietic Extracellular RNAs and Vesicles in the Lung during Allergic Airway Responses. Cell Rep. 2019,26, 933–944.e4. [CrossRef] [PubMed] 139. Levänen, B.; Bhakta, N.R.; Paredes, P.T.; Barbeau, R.; Hiltbrunner, S.; Pollack, J.L.; Sköld, C.M.; Svartengren, M.; Grunewald, J.; Gabrielsson, S.; et al. Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients. J. Allergy Clin. Immunol. 2013,131, 894–903.e8. [CrossRef] 140. Fujita, Y.; Araya, J.; Ito, S.; Kobayashi, K.; Kosaka, N.; Yoshioka, Y.; Kadota, T.; Hara, H.; Kuwano, K.; Ochiya, T. Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. J. Extracell. Vesicles 2015 ,4, 28388. [CrossRef] 141. Xu, H.; Ling, M.; Xue, J.; Dai, X.; Sun, Q.; Chen, C.; Liu, Y.; Zhou, L.; Liu, J.; Luo, F.; et al. Exosomal microRNA-21 derived from bronchial epithelial cells is involved in aberrant epithelium-fibroblast cross-talk in COPD induced by cigarette smoking. Theranostics 2018,8, 5419–5433. [CrossRef] 142. Héliot, A.; Landkocz, Y.; Saint-Georges, F.R.; Gosset, P.; Billet, S.; Shirali, P.; Courcot, D.; Martin, P.J. Smoker extracellular vesicles influence status of human bronchial epithelial cells. Int. J. Hyg. Environ. Heal. 2017,220, 445–454. [CrossRef] 143. Makiguchi, T.; Yamada, M.; Yoshioka, Y.; Sugiura, H.; Koarai, A.; Chiba, S.; Fujino, N.; Tojo, Y.; Ota, C.; Kubo, H.; et al. Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. Respir. Res. 2016 ,17, 1–15. [CrossRef] 144. Yao, M.-Y.; Zhang, W.-H.; Ma, W.-T.; Liu, Q.-H.; Xing, L.-H.; Zhao, G.-F. microRNA-328 in exosomes derived from M2 macrophages exerts a promotive effect on the progression of pulmonary fibrosis via FAM13A in a rat model. Exp. Mol. Med. 2019 ,51, 1–16. [CrossRef] 145. Njock, M.-S.; Guiot, J.; A Henket, M.; Nivelles, O.; Thiry, M.; Dequiedt, F.; Corhay, J.-L.; E Louis, R.; Struman, I. Sputum exosomes: Promising biomarkers for idiopathic pulmonary fibrosis. Thorax 2018,74, 309–312. [CrossRef] [PubMed] 146. Park, J.-A.; Sharif, A.S.; Tschumperlin, D.J.; Lau, L.; Limbrey, R.; Howarth, P.; Drazen, J.M. Tissue factor–bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. J. Allergy Clin. Immunol. 2012,130, 1375–1383. [CrossRef] [PubMed] 147. Najrana, T.; Mahadeo, A.; Abu-Eid, R.; Kreienberg, E.; Schulte, V.; Uzun, A.; Schorl, C.; Goldberg, L.; Quesenberry, P.; SanchezEsteban, J. Mechanical stretch regulates the expression of specific miRNA in extracellular vesicles released from lung epithelial cells. J. Cell. Physiol. 2020,235, 8210–8223. [CrossRef] [PubMed] 148. Draijer, C.; Speth, J.M.; Penke, L.R.K.; Zaslona, Z.; Bazzill, J.D.; Lugogo, N.; Huang, Y.J.; Moon, J.J.; Peters-Golden, M. Resident alveolar macrophage-derived vesicular SOCS3 dampens allergic airway inflammation. FASEB J. 2020 ,34, 4718–4731. [CrossRef] [PubMed] 149. Cañas, J.A.; Sastre, B.; Mazzeo, C.; Fernández-Nieto, M.; Muñoz, J.M.R.; González-Guerra, A.; Izquierdo, M.; Barranco, P.; Quirce, S.; Sastre, J.; et al. Exosomes from eosinophils autoregulate and promote eosinophil functions. J. Leukoc. Biol. 2017 ,101, 1191–1199. [CrossRef] [PubMed] 150. Cañas, J.A.; Sastre, B.; Rodrigo-Muñoz, J.M.; Fernández-Nieto, M.; Barranco, P.; Quirce, S.; Sastre, J.; Del Pozo, V. Eosinophilderived exosomes contribute to asthma remodelling by activating structural lung cells. Clin. Exp. Allergy 2018 ,48, 1173–1185. [CrossRef] 151. Rossaint, J.; Kühne, K.; Skupski, J.; Van Aken, H.; Looney, M.R.; Hidalgo, A.; Zarbock, A. Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response. Nat. Commun. 2016,7, 13464. [CrossRef] 152. Cañas, J.A.; Sastre, B.; Muñoz, J.M.R.; Del Pozo, V. Exosomes: A new approach to asthma pathology. Clin. Chim. Acta 2019 ,495, 139–147. [CrossRef] 153. Lu, T.X.; Munitz, A.; Rothenberg, M.E. MicroRNA-21 Is Up-Regulated in Allergic Airway Inflammation and Regulates IL-12p35 Expression. J. Immunol. 2009,182, 4994–5002. [CrossRef] 154. Elbehidy, R.M.; Youssef, D.M.; El-Shal, A.S.; Shalaby, S.M.; Sherbiny, H.S.; Sherief, L.M.; Akeel, N.E. MicroRNA–21 as a novel biomarker in diagnosis and response to therapy in asthmatic children. Mol. Immunol. 2016,71, 107–114. [CrossRef] 155. Gon, Y.; Maruoka, S.; Inoue, T.; Kuroda, K.; Yamagishi, K.; Kozu, Y.; Shikano, S.; Soda, K.; Lötvall, J.; Hashimoto, S. Selective release of miRNAs via extracellular vesicles is associated with house-dust mite allergen-induced airway inflammation. Clin. Exp. Allergy 2017,47, 1586–1598. [CrossRef] [PubMed] Int. J. Mol. Sci. 2021,22, 583 19 of 20 156. Moon, H.-G.; Kim, S.-H.; Gao, J.; Quan, T.; Qin, Z.; Osorio, J.C.; Rosas, I.O.; Wu, M.; Tesfaigzi, Y.; Jin, Y. CCN1 secretion and cleavage regulate the lung epithelial cell functions after cigarette smoke. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014 ,307, L326–L337. [CrossRef] [PubMed] 157. Shiomi, T.; Okada, Y.; Foronjy, R.; Schiltz, J.; Jaenish, R.; Krane, S.; D’Armiento, J. Emphysematous Changes Are Caused by Degradation of Type III Collagen in Transgenic Mice Expressing MMP-1. Exp. Lung Res. 2003,29, 1–15. [CrossRef] [PubMed] 158. Kasahara, Y.; Tuder, R.M.; Taraseviciene-Stewart, L.; Le Cras, T.D.; Abman, S.; Hirth, P.K.; Waltenberger, J.; Voelkel, N.F. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Investig. 2000,106, 1311–1319. [CrossRef] 159. Li, C.-J.; Liu, Y.; Chen, Y.; Yu, D.; Williams, K.J.; Liu, M.-L. Novel Proteolytic Microvesicles Released from Human Macrophages after Exposure to Tobacco Smoke. Am. J. Pathol. 2013,182, 1552–1562. [CrossRef] 160. Cordazzo, C.; Petrini, S.; Neri, T.; Lombardi, S.; Carmazzi, Y.; Pedrinelli, R.; Paggiaro, P.; Celi, A. Rapid shedding of proinflammatory microparticles by human mononuclear cells exposed to cigarette smoke is dependent on Ca2+ mobilization. Inflamm. Res. 2014,63, 539–547. [CrossRef] 161. Kaur, G.; Singh, K.; Maremanda, K.; Li, D.; Chand, H.S.; Rahman, I. Differential Plasma Exosomal Long Non-Coding RNAs Expression Profiles and Their Emerging Role in E-Cigarette Users, Cigarette, Waterpipe, and Dual Smokers. Plos One. 2020 ,15, e0243065. [CrossRef] 162. He, S.; Chen, D.; Hu, M.; Zhang, L.; Liu, C.; Traini, D.; Grau, G.E.; Zeng, Z.; Lu, J.; Zhou, G.; et al. Bronchial epithelial cell extracellular vesicles ameliorate epithelial-mesenchymal transition in COPD pathogenesis by alleviating M2 macrophage polarization. Nanomed. Nanotechnol. Biol. Med. 2019,18, 259–271. [CrossRef] 163. Serban, K.A.; Rezania, S.; Petrusca, D.N.; Poirier, C.; Cao, D.; Justice, M.J.; Patel, M.; Tsvetkova, I.; Kamocki, K.; Mikosz, A.; et al. Structural and functional characterization of endothelial microparticles released by cigarette smoke. Sci. Rep. 2016 ,6, 31596. [CrossRef] 164. Gordon, C.; Gudi, K.; Krause, A.; Sackrowitz, R.; Harvey, B.-G.; Strulovici-Barel, Y.; Mezey, J.G.; Crystal, R.G. Circulating Endothelial Microparticles as a Measure of Early Lung Destruction in Cigarette Smokers. Am. J. Respir. Crit. Care Med. 2011 ,184, 224–232. [CrossRef] 165. Liu, G.; Friggeri, A.; Yang, Y.; Milosevic, J.; Ding, Q.; Thannickal, V.J.; Kaminski, N.; Abraham, E.H. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 2010,207, 1589–1597. [CrossRef] [PubMed] 166. Borges, F.T.; Melo, S.A.; Özdemir, B.C.; Kato, N.; Revuelta, I.; Miller, C.A.; Ii, V.H.G.; LeBleu, V.S.; Kalluri, R. TGFβ 1–Containing Exosomes from Injured Epithelial Cells Activate Fibroblasts to Initiate Tissue Regenerative Responses and Fibrosis. J. Am. Soc. Nephrol. 2012,24, 385–392. [CrossRef] 167. Szul, T.; Bratcher, P.E.; Fraser, K.B.; Kong, M.; Tirouvanziam, R.; Ingersoll, S.; Sztul, E.; Rangarajan, S.; Blalock, J.E.; Xu, X.; et al. Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes. Am. J. Respir. Cell Mol. Biol. 2016,54, 359–369. [CrossRef] 168. Hough, K.P.; Wilson, L.S.; Trevor, J.L.; Strenkowski, J.G.; Maina, N.; Kim, Y.-I.; Spell, M.L.; Wang, Y.; Chanda, D.; Dager, J.R.; et al. Unique Lipid Signatures of Extracellular Vesicles from the Airways of Asthmatics. Sci. Rep. 2018 ,8, 10340. [CrossRef] [PubMed] 169. Lässer, C.; E O’Neil, S.; Ekerljung, L.; Ekström, K.; Sjöstrand, M.; Lötvall, J. RNA-containing Exosomes in Human Nasal Secretions. Am. J. Rhinol. Allergy 2011,25, 89–93. [CrossRef] [PubMed] 170. Lässer, C.; O’Neil, S.E.; Shelke, G.V.; Sihlbom, C.; Hansson, S.F.; Gho, Y.S.; Lundbäck, B.; Lötvall, J. Exosomes in the nose induce immune cell trafficking and harbour an altered protein cargo in chronic airway inflammation. J. Transl. Med. 2016 ,14, 181. [CrossRef] 171. Zhang, W.; Zhang, J.; Cheng, L.; Ni, H.; You, B.; Shan, Y.; Bao, L.; Wu, D.; Zhang, T.; Yue, H.; et al. A disintegrin and metalloprotease 10-containing exosomes derived from nasal polyps promote angiogenesis and vascular permeability. Mol. Med. Rep. 2018,17, 5921–5927. [CrossRef] 172. Cruz, F.F.; Borg, Z.D.; Goodwin, M.; Sokocevic, D.; Wagner, D.E.; Coffey, A.; Antunes, M.; Robinson, K.L.; Mitsialis, S.A.; Kourembanas, S.; et al. Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles AmelioratesAspergillusHyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice. Stem Cells Transl. Med. 2015,4, 1302–1316. [CrossRef] 173. Fang, S.; Zhang, H.; Wang, C.; He, B.; Liu, X.; Meng, X.; Peng, Y.; Xu, Z.; Fan, X.; Wu, Z.; et al. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p. J. Extracell. Vesicles 2020,9, 1723260. [CrossRef] 174. Du, Y.-M.; Zhuansun, Y.-X.; Chen, R.; Lin, L.; Lin, Y.; Li, J.-G.; Yu-Mo, D.; Yong-Xun, Z.; Rui, C.; Ying, L.; et al. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. Exp. Cell Res. 2018,363, 114–120. [CrossRef] 175. Burke, H.; Freeman, A.; Ostridge, K.; Staples, K.J.; Spalluto, M.; Wilkinson, T. Lung exosomal miRNAs discriminate between healthy ex-smokers and COPD. In Airway Cell Biology and Immunopathology; European Respiratory Society (ERS): Lausanne, Switzerland, 2019; Volume 5, p. 212. 176. Mohamed, A.; Pekoz, A.Y.; Ross, K.; Hutcheon, G.A.; Saleem, I.Y. Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD. Int. J. Pharm. 2019,569, 118524. [CrossRef] [PubMed] 177. Zhang, D.; Lee, H.; Wang, X.; Rai, A.; Groot, M.; Jin, Y. Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses. Mol. Ther. 2018,26, 2119–2130. [CrossRef] [PubMed] Int. J. Mol. Sci. 2021,22, 583 20 of 20 178. Li, M.; Jiang, M.; Meng, J.; Tao, L. Exosomes: Carriers of Pro-Fibrotic Signals and Therapeutic Targets in Fibrosis. Curr. Pharm. Des. 2020,25, 4496–4509. [CrossRef] [PubMed] 179. Mansouri, N.; Willis, G.R.; Fernandez-Gonzalez, A.; Reis, M.; Nassiri, S.; Mitsialis, S.A.; Kourembanas, S. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes. JCI Insight 2019 , 4. [CrossRef] [PubMed] 180. Shentu, T.-P.; Huang, T.-S.; Cernelc-Kohan, M.; Chan, J.; Wong, S.S.; Espinoza, C.R.; Tan, C.; Gramaglia, I.; Van Der Heyde, H.; Chien, S.; et al. Thy-1 dependent uptake of mesenchymal stem cell-derived extracellular vesicles blocks myofibroblastic differentiation. Sci. Rep. 2017,7, 18052. [CrossRef]